Log In
Print
BCIQ
Print
Print this Print this
 

rhGUS (UX003)

  Manage Alerts
Collapse Summary General Information
Company Ultragenyx Pharmaceutical Inc.
DescriptionRecombinant human glucuronidase beta (rhGUS)
Molecular Target
Mechanism of ActionEnzyme replacement therapy
Therapeutic ModalityBiologic: Enzyme
Latest Stage of DevelopmentPhase I/II
Standard IndicationMucopolysaccharidosis
Indication DetailsTreat mucopolysaccharidosis VII (MPS VII; Sly syndrome)
Regulatory Designation

U.S. - Orphan Drug (Treat mucopolysaccharidosis VII (MPS VII; Sly syndrome));
EU - Orphan Drug (Treat mucopolysaccharidosis VII (MPS VII; Sly syndrome))

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today